THE European Medicine Agency’s
Committee for Medicinal Products
for Human Use has recommended
marketing authorisation for
pomalidomide to treat patients
with multiple myeloma.
The committee concluded
that the benefits of the drug in
combination with dexamethasone
outweigh its risks in patients
who have received at least two
prior therapies, including both
lenalidomide and bortezomib, and
whose disease progressed after
treatment with those medicines.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jun 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.